巴瑞替尼与托珠单抗在COVID-19住院患者中的比较有效性:美国国家COVID协作组的回顾性队列研究
该多中心回顾性队列研究采用目标试验模拟和倾向评分逆概率治疗加权,比较巴瑞替尼与托珠单抗在COVID-19住院成人中的有效性,数据来自美国国家COVID队列协作组(N3C)75家医院。共纳入10661例,6229例(58.4%)使用巴瑞替尼,4432例(41.6%)使用托珠单抗,平均年龄60.0±15.1岁,60.3%为男性,19.2%接受有创机械通气。加权后巴瑞替尼与更低的28天死亡率(OR 0.91;95%CI 0.85-0.98)、住院死亡率(OR 0.88;95%CI 0.82-0.94)、更短的住院时间(发生率比0.92;95%CI 0.90-0.94)及更低的医院获得性感染率(OR 0.86;95%CI 0.75-0.99)相关,两组ICU住院时间无差异。
要点
- 加权后巴瑞替尼较托珠单抗与更低的28天死亡率相关(OR 0.91;95%CI 0.85-0.98)。
- 巴瑞替尼组住院死亡率更低(OR 0.88;95%CI 0.82-0.94)。
- 巴瑞替尼组住院时间更短(发生率比0.92;95%CI 0.90-0.94),两组ICU住院时间无差异。
- 巴瑞替尼组医院获得性感染率更低(OR 0.86;95%CI 0.75-0.99)。
- 队列中19.2%接受有创机械通气,结果来自美国75家医院的真实世界数据。
适用人群与场景
- 因COVID-19住院的成人患者,新起始巴瑞替尼或托珠单抗治疗。
- 数据来自美国国家COVID队列协作组(N3C)75家医院。
研究设计与关键结果
- 研究设计:多中心、回顾性、倾向加权队列研究,采用目标试验模拟方法;共纳入10661例,其中巴瑞替尼组6229例(58.4%),托珠单抗组4432例(41.6%)。
- 队列平均年龄60.0±15.1岁,男性6429例(60.3%),19.2%接受有创机械通气。
- 主要终点28天死亡率:巴瑞替尼较托珠单抗降低(OR 0.91;95%CI 0.85-0.98)。
- 住院死亡率:巴瑞替尼较托珠单抗降低(OR 0.88;95%CI 0.82-0.94)。
- 住院时间:巴瑞替尼较托珠单抗缩短(发生率比0.92;95%CI 0.90-0.94);两组ICU住院时间无差异。
- 医院获得性感染:巴瑞替尼较托珠单抗降低(OR 0.86;95%CI 0.75-0.99)。
证据类型、等级与局限
- 证据类型:多中心回顾性队列研究,采用倾向评分逆概率治疗加权和目标试验模拟。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在这一大型、多样化的美国COVID-19住院成人队列中,巴瑞替尼较托珠单抗与显著更低的28天死亡率、住院死亡率、更短的住院时间及更少的医院获得性感染相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: COVID-19 treatment guidelines recommend baricitinib or tocilizumab for the management of hospitalized patients with COVID-19. We compared the effectiveness of baricitinib vs. tocilizumab on mortality and clinical outcomes among hospitalized patients with COVID-19.
DESIGN: Multicenter, retrospective, propensity-weighted cohort study using a target trial emulation approach.
SETTING: The National COVID Cohort Collaborative (N3C), which is the largest electronic health records data on COVID-19 in the United States. The setting included 75 hospitals.
PATIENTS: Adults who were hospitalized for COVID-19.
INTERVENTIONS: Newly initiated on baricitinib or tocilizumab.
MEASUREMENTS AND MAIN RESULTS: Our primary outcome was 28-day mortality. We used propensity scores with inverse probability of treatment weights (IPTWs) to control bias and confounding while comparing treatments. Among 10,661 individuals included in the study, 6,229 (58.4%) received baricitinib and 4,432 (41.6%) tocilizumab. Overall, the mean age of the cohort was 60.0 ± 15.1 years, 6429 (60.3%) were male, and 19.2% received invasive mechanical ventilation. After IPTW adjustment, baricitinib use was associated with lower 28-day mortality (odds ratio [OR], 0.91; 95% CI, 0.85-0.98) and hospital (OR, 0.88; 95% CI, 0.82-0.94) mortality compared with tocilizumab. Baricitinib was also associated with shorter hospital length of stay (incident rate ratio, 0.92; 95% CI, 0.90-0.94) and lower rates of hospital-acquired infections (OR, 0.86; 95% CI, 0.75-0.99), although no difference in ICU length of stay was noted between the two groups.
CONCLUSIONS: In this large, diverse cohort of U.S. hospitalized adults with COVID-19, baricitinib was associated with significantly lower 28-day mortality, hospital mortality, shorter hospital length of stay, and less hospital-acquired infections compared with tocilizumab.
参考来源
- Patanwala AE, Xiao X, Hills TE, et al. Comparative Effectiveness of Baricitinib Versus Tocilizumab in Hospitalized Patients With COVID-19: A Retrospective Cohort Study of the National Covid Collaborative. Crit Care Med. 2024. PMID: 39365115. doi:10.1097/CCM.0000000000006444
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。